{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "02e24043f82607db5c500d397e8f9f22",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/Time to Revisit Nxera Reiterating BuyTime to Revisit Nxera Reiterating Buy_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:22:46.051729",
      "extracted_at": "2025-10-26T12:22:46.051739"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 21,
        "successful_pages": 21,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 3,
          "removed_paragraphs": 5,
          "reduction_ratio": 0.11205654557585021
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "081f94460d76ffe8",
      "text": "Japan | Biotechnology Nxera Pharma",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "525b8f56f4803a6b",
      "text": "Time to Revisit Nxera, Reiterating Buy",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "58c47ef50272e365",
      "text": "We believe this is an optimal time to revisit Nxera, following the discontinuation of PF'522 development and the subsequent de- risking of Nxera. We view the stock as significantly undervalued, supported by three key factors: 1) a strong CNS- focused pipeline, 2) stable cash flow from its domestic pharmaceutical sales business, and 3) potential for cost efficiency improvements. We raise our target price to ¥2,400 and reiterate our Buy rating.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "0619b63c06d52567",
      "text": "Abundant opportunities in CNS area. Nxera has impressive track record in the CNS field, including the advancement of a schizophrenia program (NBI- 568) into Ph3 trials by Neurocrine and the creation of a potentially best- in- class OX2 agonist (ORX750) developed by Centessa. Furthermore, its follow- on pipeline of muscarinic agonists (NBI- 567, NBI- 569 and NBI- 570) and orexin agonists (ORX142 and ORX489) could be used for a broader range of CNS disorders, enhancing Nxera's value further. We also emphasize the strong safety profile of Nxera- derived programs, which is particularly important in CNS indications, where diseases are generally non- lethal and adverse effects can materially worsen the risk- benefit balance. Key upcoming catalysts include Ph1 data readout for muscarinic agonists, ORX142 and GPR52, which we expect positive results given the safety profile track record.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "bfbf3dac45b2c113",
      "text": "Domestic business could be a cash generator. Nxera has already achieved positive core OP of ¥3.3bn in its domestic business in 1H FY25, driven by sales of Pivlaz. With continued growth of Quviviq, we estimate that annual CF from the domestic segment could exceed ¥10bn in three years. Nxera is currently repaying debt from the Idorsia acquisition at a pace of \\(\\sim\\) ¥6bn per year, which can be fully covered by domestic CF. Once the debt is repaid, this CF can be redirected to fund R&D in the Drug Discovery segment, and we believe Nxera can continue to generate new clinical candidates without increasing debt.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c690d97e7044b0d3",
      "text": "Room for cost efficiency improvements. Nxera's SG&A and R&D expenses (¥28bn in FY24) appear relatively high compared to peers with similar platform- based business models. However, as Pivlaz approaches peak sales, SG&A related to the commercial business is expected to decline. While significant reductions in R&D spending may be challenging due to the concentration of costs in the UK, Nxera appears to be increasingly focused on improving efficiency, including narrowing the scope of early- stage programs.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "0cf73162ed433299",
      "text": "Rising price target We reflect 1H results and exclude the value of Pfizer's PF- 522 from our estimates, while incorporating the value of muscarinic agonists (NBI- 567, NBI- 569, NBI- 570) and ORX142. We also reflect a potential reduction in COGS for Quviviq sales, raising the gross margin assumption at peak sales from 30% to 40%. As a result, we revise our 10y DCF- based target price from ¥2,000 to ¥2,400. As we believe the upcoming catalysts include low risk positive catalysts, this could be a great opportunity to revisit Nxera.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "695b8e476fc38d8e",
      "text": "Details continued on the next page.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8e9c36a5aaca9d21",
      "text": "TARGET | ESTIMATE CHANGE",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "25f3e7da8f7e7ef8",
      "text": "TARGET | ESTIMATE CHANGERATINGBUYPRICE¥912*PRICE TARGET | % TO PT↑¥2,400 (¥2,000) + 163%52W HIGH-LOW¥1,500 - ¥668FLOAT (%) | ADV MM (USD)82.2% | 4.96MARKET CAP¥82.08 | $554.3MTICKER4565 JP",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4a8b015eed436bec",
      "text": "\\*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "05b23ccf215b80f4",
      "text": "FY (Dec)CHANGE TO JEFEJEF vs CONS2025202620252026REV+3%+12%+12%-1%EPS-24%+197%+4,635%-10%2025 (¥)Q1Q2Q3Q4FY12EPS----¥26.91PREV35.42",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3c1403445aad1e8f",
      "text": "Exhibit 1 - Nxera CNS pipeline",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "797450c6f1c5efcb",
      "text": "Nxera's NxWave platform continues to generate promising leads. The company has developed a stable business that is self- funding, but also has large potential upside. Key drivers for the stock include the progress of candidates discovered on its platform but developed by third parties.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "24bf64bf3e1645db",
      "text": "Base Case, ￥2400, +163%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e2f5bd83086afebd",
      "text": "Base case PT of ¥2,400 is based on 10- year DCF through FY12/34.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "aaa8df3089178d24",
      "text": "Upside Scenario, ￥5400, +492%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "26265c34492cb15b",
      "text": "Best case PT of ¥5,400 is based on 10- year DCF through FY12/34 and 20% PoS for Pfizer's GLP- 1 drug, which is licensed from Nxera.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "34f4b9f5871022d0",
      "text": "Downside Scenario, ￥600, - 34%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0b15201fef5febef",
      "text": "Worst case PT of ¥1,000 is based on 10- year DCF through FY12/34 and failure of Neurocrine's M4 agonist, which are licensed from Nxera.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "44005503fa21f61d",
      "text": "Top Material Issue(s): 1) Business Model Resilience - Nxera relies on R&D to replenish its portfolio of marketed products. R&D productivity is extremely hard to measure. Without a consistent rate of new product launches, Nxera may struggle to grow revenues. 2) Access & Affordability - The global pharma industry has attracted a lot of criticism for the high and rising prices of new medicines, which can make it hard or impossible for less wealthy people to access the best medicines.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f966fd0434de351a",
      "text": "Company Target(s): Nxera have not disclosed the corporate targets.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ac0129af28f662dc",
      "text": "Qs to Mgmt: 1) Do you aim to net carbon zero by 2050? If so, when do you plan to achieve the goal? 2) Do you set your target of female executive/management ratios?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7b295071a83fc29d",
      "text": "- Ph2 data readout of ORX750 for narcolepsy by Centessa- Ph2 data readout of TMP-301 for substance abuse by Tempero Bio- Top-line results of Ph1 for NBI-567, 569 and 570 by Neurocrine in 2H FY25",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "77ddcf51a18c9d17",
      "text": "Nxera has impressive track record in the CNS field, including the advancement of a schizophrenia program (NBI- 568) into Ph3 trials by Neurocrine and the creation of a potentially best- in- class OX2 agonist (ORX750) developed by Centessa. Furthermore, its follow- on pipeline of muscarinic agonists (NBI- 567, NBI- 569 and NBI- 570) and orexin agonists (ORX142 and ORX489) could be used for a broader range of CNS disorders, enhancing Nxera's value further. We also emphasize the strong safety profile of Nxera- derived programs, which is particularly important in CNS indications, where diseases are generally non- lethal and adverse effects can materially worsen the risk- benefit balance. Key upcoming catalysts include Ph1 data readout for muscarinic agonists, ORX142 and GPR52, which we expect positive results given the safety profile track record.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1deea931b1453b5c",
      "text": "Nxera out- licensed NBI- 568 to Neurocrine in 2021, and Ph2 data for schizophrenia was released in August last year. While the 20mg dose demonstrated statistically significant efficacy, the lack of dose dependency and signs of waning effect at week 6 led to a negative market reaction. As a result, Nxera's share price declined from \\(1,700 to\\) 1,400, and we believe current share price of \\(900 does not include most of NBI- 568 value. However, given that statistically significant efficacy was observed between weeks 3 and 6, we believe a greater portion of NBI- 568's value should be reflected in the current valuation.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "41d8e021870a8904",
      "text": "Exhibit 3 - NBI-568 Ph2 data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "50657212f67e86fb",
      "text": "Source: Company info., Jefferies",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f5a293592f830ead",
      "text": "While market concerns around the Ph3 trial of NBI- 568 center on efficacy, we take a more optimistic view. The Ph2 study did not show clear dose dependency, but we believe this reflects a characteristic of psychiatric disorders, where therapeutic effect is not necessarily enhanced by higher doses. In such conditions, precise modulation of target activity is more important than strong inhibition or activation. Although the waning effect observed at week 6 is a concern, the trial had a small sample size ( \\(n = 40\\) in 20mg cohort), and site- specific or patient- specific factors may have influenced the outcome. Importantly, statistically significant efficacy was still observed at week 6. Furthermore, Neurocrine has introduced an inclusion criterion of PANSS score \\(\\geq 85\\) for the Ph3 trial, which focuses on more severe patients. This may increase the likelihood of detecting a clearer placebo- adjusted effect. For these reasons, we believe the probability of NBI- 568 reaching the market remains high.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "113291f1b69188f3",
      "text": "Exhibit 4-NBI-568 clinical trial design",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2c1b3a25fb66897f",
      "text": "Ph3Ph2SCZ3029SCZ3030SCZ2028Primary endpointChange in PANSS score at Week 5Change in PANSS score at Week 6Ages18 years to 65 years18 years to 55 yearsSeverityPANSS &amp;gt;= 85PANSS &amp;gt;= 80N284284210LocationUSEUUSNumber of sites11ND15",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2cb65ea2aeb90da6",
      "text": "Source: Company info, Clinical Trials.gov",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1185b2eb169f4b8a",
      "text": "In terms of safety, NBI- 568 has demonstrated a strong profile, likely due to its high selectivity for the M4 receptor. Among muscarinic agonists, M2 is associated with gastrointestinal side effects and M3 with cardiovascular events. However, NBI- 568 showed less than \\(5\\%\\) incidence for both, with no significant difference compared to placebo. In contrast, the competing drug Cobenfy acts not only on M4 but also on M1, and its limited selectivity leads to off- target effects on M2 and M3. We believe NBI- 568's mechanism- driven safety is reproducible in Ph3 trials. Additionally, while Cobenfy requires dietary restrictions, no such limitations have been reported for NBI- 568 to date.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a3eef4571a14f052",
      "text": "Exhibit 5 - Major adverse events of NBI-568 and Cobenfy",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "74f7d005e2865422",
      "text": "NBI-568 Ph2CobenfyNBI-568 (20mg)PlaceboCobenfyPlaceboNausea5%3%19%4%Dyspepsia&amp;lt;5%&amp;lt;5%18%5%Costipation5%3%17%7%Vomitting&amp;lt;5%&amp;lt;5%15%1%Hypertension&amp;lt;5%&amp;lt;5%11%2%Somnolence13%3%3%2%Dizziness13%1%5%2%Headache3%20%&amp;lt;2%&amp;lt;2%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "632b7e4e3117ba45",
      "text": "Source: Company info, Cobenfy package insert",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "46ae46b17585d2b4",
      "text": "Following NBI- 568, Nxera has further muscarinic agonist pipeline partnering with Neurocrine, including NBI- 567 (M1- preferred agonist), NBI- 569 (M4- preferred agonist), and NBI- 570 (M1/M4 dual agonist). All three compounds are currently undergoing Ph1 trials, with data readouts expected later this year. Neurocrine plans to release the Ph1 results for all three simultaneously. Notably, Neurocrine has already announced plans to initiate a Ph2 trial for NBI- 570 within this year, implying a low likelihood of failure in Ph1.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "670442c9aef7b140",
      "text": "We view the upcoming data readouts as a positive catalyst. According to patent US10961225B2, Neurocrine's muscarinic agonists appear to share the same bicyclic aza structure as NBI- 568, which has already demonstrated a favorable safety profile. Given this structural consistency, we do not anticipate major safety concerns. Since Ph1 trials are primarily designed to assess safety, we expect the results to be positive.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "97c531ee7912a975",
      "text": "Severe schizophrenia patients will be enrolled in Ph3",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4c6d8df557a58129",
      "text": "NBI- 568 showed mechanism- driven safety profile",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "abc44c39e93603f9",
      "text": "Exhibit 6 - Common structure in Neurocrine's muscarinic agonists",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "662d4ba2c52db9f4",
      "text": "Source: Google patent",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "fd3b7203f0edc835",
      "text": "Also, patent US10961225B2 references a wide range of potential indications for muscarinic agonists, including numerous psychiatric and neurological disorders. While the currently disclosed development programs focus on schizophrenia and bipolar disorder, the underlying mechanism may allow expansion into broader indications such as Alzheimer's disease, ADHD, and Parkinson's disease. This suggests significant upside potential beyond the current pipeline.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1d0eda20543855da",
      "text": "2.19 A compound for use in according to Embodiment 2.18 wherein the cognitive disorder or psychotic disorder comprises, arises from or is associated with a condition selected from cognitive impairment, Mild Cognitive Impairment, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, presenile dementia, senile dementia, Friederich's ataxia, Down's syndrome, Huntington's chorea, hyperkinesia, mania, Tourette's syndrome, Alzheimer's disease, progressive supranuclear palsy, impairment of cognitive functions inducing attention, orientation, learning disorders, memory (i.e. memory disorders, amnesia, amnesic disorders, transient global amnesia syndrome and age- associated memory impairment) and language function; cognitive impairment as a result of stroke, Huntington's disease, Pick disease, Aids- related dementia or other dementia states such as Multifract dementia, alcoholic dementia, hypotiroidism- related dementia, and dementia associated to other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis; other acute or sub- acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug- induced states neurotoxic agents, age related cognitive impairment, autism related cognitive impairment, Down's syndrome, cognitive deficit related to psychosis, and post- electroconvulsive treatment related cognitive disorders; cognitive disorders due to drug abuse or drug withdrawal including nicotine, cannabis, amphetamine, cocaine. Attention Deficit Hyperactivity Disorder (ADHD) and dyskinetic disorders such as Parkinson's disease, neuroleptic- induced parkinsonism and tardive dyskinesias, schizophrenia, schizophrenia- reform disorders, psychotic depression, mania, acute mania, paranoid, hallucinogenic and delusional disorders, personality disorders, obsessive compulsive disorders, schizotypal disorders, delusional disorders, psychosis due to malignancy, metabolic disorder, endocrine disease or narcolepsy, psychosis due to drug abuse or drug withdrawal, bipolar disorders, epilepsy and schizo- affective disorder.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c4a8354efe2db72a",
      "text": "Source: Google Patent",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "ef977f0c4ec75b94",
      "text": "We estimate that Nxera's royalty income from muscarinic agonist portfolio (NBI- 567, NBI- 568, NBI- 569, NBI- 570) will contribute \\(\\sim \\yen 11\\) bn in revenue by FY12/36, adjusted for PoS. Our base",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b1e68e6f7aa0bc3b",
      "text": "Nxera- drived muscarinic agonists has same core structure",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "28b7dce2cc6eab44",
      "text": "Huge potential in target indications",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "fbf151c2c404131b",
      "text": "assumption is a combined unadjusted peak sales potential of ¥700bn across the four compounds, to which we apply a weighted average PoS of \\(13\\%\\) in FY12/36. Regarding royalty rate, Nxera disclosed that it is entitled to receive tiered royalties, with the maximum rate reaching the mid- \\(10\\%\\) range.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9014e171ba50df51",
      "text": "Exhibit 8 - Potential royalty income from muscarinic agonists (after PoS adjustment)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8a37902749e76994",
      "text": "Source: Jefferies estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "4f74c23c32f993cc",
      "text": "ORX750 is a compound being developed by Centessa for sleep disorders. It is currently in the Ph2a stage, with clinical trials targeting patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia (IH). In the Ph1 trial results disclosed last year, ORX750 demonstrated statistically significant efficacy in healthy volunteers along with a favorable safety profile. Nxera is entitled to receive development milestones and low- single- digit royalties from this program.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c07082f7fff2e88e",
      "text": "Exhibit 9 - ORX750 Ph1 data for healthy volunteers",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "61422e0c5de5e55a",
      "text": "Source: Company info., Jefferies Note: p-values were 0.04 in 1.0mg, 0.01 in 2.0mg, \\(",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "20eb0412c7609488",
      "text": "ORX750 has shown a favorable safety profile, though the data is from healthy volunteers. In the Ph1 trial, there were no trial discontinuations due to adverse events and no serious adverse events reported. The Ph2a data is expected to be released later this year, with safety as the primary endpoint. Based on the Ph1 results, we believe the likelihood of safety- related issues emerging in Ph2a is low. Therefore, we see minimal risk of the upcoming readout acting as a negative catalyst.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "eaafe76661b83675",
      "text": "Royalty income from muscarinic agonist expands",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "3269c1be703151ad",
      "text": "Exhibit 10-ORX750 Ph1 summary of TAEA",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "738f0ed17ed40175",
      "text": "SAD CohortsMAD CohortsPlacebo (N=15)ORX750 1.0mg (N=9)ORX750 2.0mg (N=9)ORX750 2.5mg (N=9)ORX750 3.5mg (N=9)ORX750 5.0mg (N=9)Placebo (N=6)ORX750 2.0mg (N=8)ORX750 3.0mg (N=8)ORX750 4.0mg (N=8)TEAEs leading to discontinuation (%)0%0%0%0%0%00%0%0%0%Serious TEAEs (%)0%0%0%0%0%00%0%0%0%Any TEAE (%)27%33%33%11%0%33%50%50%50%75%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a4cfd32cf6058417",
      "text": "Source: Company info. In the Ph2a trial, efficacy will be assessed as a secondary endpoint using MwT, ESS, and cataplexy rate (for NT1 only). For NT1, where competing therapies have already demonstrated clear efficacy in MWT and ESS, attention will likely focus on cataplexy reduction and efficacy at lower doses. In NT2 and IH, Takeda has discontinued development of TAK-861 in these indications, and if ORX750 shows efficacy, it could offer a clear competitive advantage.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "fbf039d0ee6f9c18",
      "text": "ORX142, ORX489Following ORX750, Centessa is developing ORX142 and ORX489, both of which were discovered through Nxera's platform. Nxera retains rights to receive royalties from these programs. ORX142 exhibits higher selectivity for OX2R (13,000x) over OX1R compared to ORX750 (9,800x), while ORX489 shows a higher affinity for OX2R, with an EC50 of 0.035 nM which is comparable to native orexin A. These profiles suggest potential applicability in a broader range of indications, including neurodegenerative diseases.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "99c1922c36ff2e18",
      "text": "Exhibit 11 - Selectivity of Nxera-derived OX2R agonists",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "8940ab2e183c7ba0",
      "text": "OX2R EC50 (nM)Selectivity vs. OX1RNative ligand OXA0.035NAORX7500.1109,800xORX1420.06913,000xORX4890.0358,800x",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "d884f960cec80cac",
      "text": "Source: Company info.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "5343b9851d9b5294",
      "text": "As the next catalyst, ORX142 is expected to generate Ph1 data in healthy volunteers during 2025. Centessa plans to assess safety across multiple cohorts, with Parts A to D including participants aged 18 to 55, and Part E focusing on older adults aged 60 to 80. If safety is confirmed in elderly populations, it would represent meaningful progress toward expanding indications beyond sleep disorders, potentially into psychiatric conditions.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7f1edebdff795856",
      "text": "Regarding ORX489, IND- enabling data is expected to be available within this year. Its high affinity for OX2R suggests that efficacy may be achievable at lower doses, supporting a high likelihood of IND approval. Additionally, while its selectivity for OX2R over OX1R is slightly lower than that of ORX750 or ORX142, its selectivity ratio of 8,800x exceeds that of TAK- 861 (3,000x) by a significant margin, which we believe is more than sufficient.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "78c07aa3d6c20c3d",
      "text": "Nxera is entitled to receive mid- single- digit royalties from Centessa on sales of these OX2R franchise compounds. We estimate total franchise sales to reach approximately ¥800bn, and apply a weighted average PoS of 30%. Based on these assumptions, we project royalty income to Nxera of ¥8bn in FY12/36.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "163fd8fdf9f79d8f",
      "text": "ORX750 showed positive safety profile",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2840ae64f62fe921",
      "text": "ORX142 and ORX489 has higher selectivity and affinity profile than ORX750",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "3389a9f655c05821",
      "text": "Exhibit 12 - Potential royalty income from OX2R agonists (after PoS adjustment)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "f43c304fd940ecfe",
      "text": "Source:Jefferies estimate",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bf44ea4febdd8e01",
      "text": "Nxera is currently conducting a Ph1 trial for its GPR52 agonist, with completion expected in 2025. In March 2024, the company entered into a global collaboration and exclusive option- to- license agreement with Boehringer Ingelheim. Under the terms of the deal, Boehringer paid €25mn upfront and holds an exclusive option to license the program upon completion of the ongoing Ph1, a subsequent Ph1b, and Ph2- enabling activities. If Boehringer exercises the option within this year, Nxera is expected to receive an additional €60mn (approximately ¥10bn), which could bring the company's consolidated earnings into positive territory. Currently we include the option execution fee in the current FY with \\(50\\%\\) PoS.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3070f224985c5da3",
      "text": "Nxera is currently conducting a Ph1 trial of its GPR52 agonist, with completion expected in 2025. GPR52 is a G protein- coupled receptor primarily expressed in the striatum and cortex, regions involved in cognition, emotion, and motor control. Activation of GPR52 modulates both dopaminergic and glutamatergic neurotransmission via the cAMP signaling pathway, offering a novel approach to treating neuropsychiatric disorders such as schizophrenia. Unlike traditional dopamine D2 receptor antagonists, which are associated with gastrointestinal side effects such as nausea and constipation, as well as metabolic issues including weight gain and insulin resistance, GPR52 agonists may alleviate both positive and negative symptoms, as well as cognitive deficits, with a more favorable safety profile. Given that this is a novel mechanism, we assign a conservative PoS of \\(5\\%\\) . However, if successful, we believe the compound could achieve global peak sales of \\(\\) 2- 3bn\\$ positioning it as a potential game- changer in the treatment of schizophrenia.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0bbf8fff4a16db28",
      "text": "TMP- 301 is an mGlu5 receptor antagonist currently in Ph2 development for alcohol use disorder and in Ph1 for cocaine use disorder. Given the competitive landscape with generics, we take a cautious view at this stage. In alcohol use disorder, Alkermes' Vivitrol (naltrexone) generated \\(\\) 457\\mathrm{mn}\\(in U.S. sales in 2024, and generic competition is expected by the time TMP - 301 launches. Campral (acamprosate calcium), another drug with a similar mechanism, is also available as a generic. Therefore, unless TMP - 301 demonstrates clearly superior efficacy, widespread adoption may be challenging. Vivitrol has shown a\\) 25\\%\\$ reduction in heavy drinking days versus placebo, while Campral increased the proportion of abstinent days over six months by \\(14\\%\\) (2g/day, among patients with a baseline goal of abstinence). We estimate peak sales for TMP- 301 in alcohol use disorder at ¥30 billion. However, with an estimated 28mn patients in the U.S. alone, the upside could be significant if both efficacy and safety are clearly demonstrated.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "921abd1db9e80881",
      "text": "Pivlaz, launched in 2022, is approved in Japan for the prevention of cerebral vasospasm, vasospasm- related cerebral infarction, and cerebral ischemic symptoms following aneurysmal subarachnoid hemorrhage (aSAH) surgery. It is primarily used in acute care hospitals. The product has already achieved a market share in the mid- \\(70\\%\\) range, and we estimate peak share will reach \\(85\\%\\) by 2027, with peak sales of \\(\\yen 15.5bn\\) . Assuming a COGS ratio of \\(15\\%\\) and core operating expenses (excluding depreciation, including SG&A and post- marketing surveillance) of approximately \\(\\yen 5bn\\) , we estimate Pivlaz could generate \\(\\yen 7bn\\) in cash flow in 2027. The patent is expected to expire in 2030. However, given its use in acute care settings, the impact of generics is expected to be limited. While price revisions are likely to reduce revenue, the decline in cash flow may be delayed due to the reduction in SG&A expenses.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "55609e3175931054",
      "text": "Exhibit 13 - Pivlaz sales forecast",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "0fd7689bb74991bb",
      "text": "Source: Jefferies estimates",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4d9443210751656a",
      "text": "Exhibit 14 - Pivlaz cash flow estimates",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "d1754eafc46e164d",
      "text": "Source: Jefferies estimates",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "03d60cbbc1f453c4",
      "text": "Quviviq was launched in December 2024 in Japan as a treatment for insomnia. The product is marketed by Shionogi, while Nxera receives revenue from product supply and royalties. Eisai's Dayvigo, which shares the same mechanism of action as Quviviq (DORA), has significantly expanded its sales by capturing share from non- DORA therapies. In FY25/3, Dayvigo generated \\(\\yen 44.5bn\\) in sales in Japan. Currently, Quviviq is subject to a two- week prescription limit, and Dayvigo is considered the preferred option in clinical practice. However, this restriction is expected to be lifted in November, which would position Quviviq on equal footing with Dayvigo. We project peak revenue from Quviviq in 2031 at \\(\\yen 12.6bn\\) , including both royalties and product",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a5f06f5a59d846ff",
      "text": "supply. On a cash flow basis, we estimate ¥6.0bn. Given that Quvivig's patent extends through 2038, we expect a longer duration of cash flow contribution compared to Pivlaz.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "1f8bd1dbf1910b89",
      "text": "Exhibit 15 - Quvivig sales forecast",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "648e43faa7648fb5",
      "text": "Source: Jefferies estimates",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5adef59fee3c40c6",
      "text": "Exhibit 16 - Quvivig cash flow estimates",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "edf54bea1167b763",
      "text": "Source: Jefferies estimates",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "7d4db37a05e9ef99",
      "text": "As of the end of June 2025, Nxera holds ¥30.0 bn in borrowings and ¥31.0 bn in convertible bonds. We believe abundant cash flow from Pivlaz and Quvivig decreases the risk associated with financial leverage. The ¥30.0 bn in borrowings is related to the acquisition of Idorsia. Nxera plans to repay approximately ¥6.0 bn annually through June 2030. This repayment amount can be covered by cash flow generated from Pivlaz alone in the current fiscal year. From the next fiscal year onward, we expect positive cash flow from the commercial business even after debt repayment. Therefore, we believe the positive impact of the Idorsia acquisition will begin to materialize from next fiscal year in terms of cash flow.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "fec409bc2062bb17",
      "text": "Nxera currently holds ¥32.0 bn in convertible bonds (CB) with a strike price of ¥1,782 and maturity in 2028. We view this as an appropriate level of leverage to efficiently operate the business. Given the strong cash flow generation from Pivlaz and Quvivig, we do not anticipate the need for additional debt financing. Looking ahead to 2028, the potential launches of Neurocrine's NBI- 568 and Centessa's ORX750 could serve as catalysts for share price appreciation. Should the stock price exceed the strike price, conversion is likely to progress, ultimately resulting in equity capitalization. The CB includes a put option allowing early redemption on December 14, 2026. If the current share price level persists until that date, early redemption may be triggered, which poses a risk. However, we believe this can be mitigated through clause amendments or refinancing.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "063574830b88ed83",
      "text": "Nxera's SG&A and R&D expenses (¥28bn in FY24) appear relatively high compared to peers with similar platform- based business models. However, as Pivlaz approaches peak sales, SG&A related to the commercial business is expected to decline. While significant reductions in R&D spending may be challenging due to the concentration of costs in the UK, Nxera appears to be increasingly focused on improving efficiency, including narrowing the scope of early- stage programs.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6a0229ca1b70e578",
      "text": "Pivlaz is expected to reach peak sales around 2027 and is already approaching a plateau. As a result, promotional activities by medical representatives (MRs) are expected to require less investment going forward, leading to a decline in SG&A expenses related to Pivlaz. Quvivig is marketed by Shionogi, and therefore Nxera does not incur direct SG&A costs for this product. Meanwhile, Nxera is planning to introduce additional domestically developed products. Depending on the product, marketing expenses may be required; however, the company utilizes",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "199b252c343295d1",
      "text": "contract sales organizations (CSOs), allowing for flexible cost management. We believe the risk of significant deterioration in cost efficiency within the commercial business remains low.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "047b3b8d9d78b242",
      "text": "Nxera incurs approximately \\(12.0bn\\) annually in R&D expenses for its Drug Discovery business. The majority of this cost is attributed to the exploration and development of earlystage programs. The company's research base is located in the UK and includes large- scale infrastructure such as cryo- electron microscopy, making significant cost reductions challenging. However, Nxera appears to be pursuing greater cost efficiency through prioritization and narrowing of early- stage programs. While structural cost reductions may be limited, selective investment is expected to improve overall R&D productivity.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f67eac4962eca78d",
      "text": "Therefore, SG&A expenses are expected to decline. While R&D costs may vary depending on the progress of in- house programs, a significant increase from the current level is unlikely. Therefore, we see limited risk of a substantial rise in total expenses through 2030, and we forecast a modest increase in operating costs of approximately \\(1\\%\\) per year in the long term.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "cb6529804fe23a7c",
      "text": "Exhibit 17 - Nxera operating costs forecast",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "9949f2de57ae81a1",
      "text": "Source: Company info., Jefferies estimates",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d0f67829bba73805",
      "text": "Therefore, we believe Nxera can enjoy returns from its current out- licensed pipeline without a significant increase in costs. As a result, we forecast FY2030 revenue of \\(49bn\\) and operating profit of \\(10bn\\) , excluding contributions from new in- licensing deals. Nxera targets \\(50bn\\) in revenue by 2030, excluding royalty income, which we believe is achievable with additional in- licensed assets.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "dcc67d7ccb1bed0b",
      "text": "Exhibit 18 - Nxera sales forecast",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "da65d57bf8a809a6",
      "text": "Source: Company info., Jefferies estimates",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "94b3aa7a56acd4d1",
      "text": "Exhibit 19 - Nxera OP forecast",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "130920e03a126fcd",
      "text": "Source: Company info., Jefferies estimates",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "28cc847bead3e10b",
      "text": "We exclude the value of Pfizer's PF- 522 from our estimates, while incorporating the value of muscarinic agonists (NBI- 567, NBI- 569, NBI- 570) and ORX142. We also reflect a potential reduction in COGS for Quviviq sales, raising the gross margin assumption at peak sales from \\(30\\%\\) to \\(40\\%\\) . As a result, we revise our 10y DCF- based target price from \\(\\) 2,000\\(to\\) \\ \\(2,400\\) . As we believe the upcoming catalysts include low risk positive catalysts, this could be a great opportunity to revisit Nxera.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "0015957275b2c849",
      "text": "Exhibit 20 -Nxera DCF analysis (Ymn)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "814950194b9e8e29",
      "text": "FY12/25EFY12/26EFY12/27EFY12/28EFY12/29EFY12/30EFY12/31EFY12/32EFY12/33EFY12/34EOperating profit2,2633,85410,4185,2558,2529,94815,67719,85623,63528,532Tax provision(453)(771)(2,084)(1,051)(1,650)(1,990)(3,135)(3,971)(4,727)(5,706)NOPAT1,8103,0838,3344,2046,6027,95812,54115,88418,90822,826+ D&A3,8003,8003,8003,8003,9003,9004,0004,0004,0004,000- CapEx(1,600)(1,700)(1,800)(1,900)(2,000)(2,100)(2,200)(2,200)(2,200)(2.200)(+)/- Change in Working Capital(831)(2,419)(2,223)(1,382)(1,483)(796)(330)(1,937)(1,751)(2,045)Free Cash Flow3,1802,7648,1124,7226,9198,96214,01215,74818,95722,581Terminal Value298,068Discount Factor1.00.90.90.80.80.70.70.60.60.6PV FCF3,1122,5406,9993,8255,2636,4019,3969,91411,20612,534Cost of Equity7.5%ERP6.0%RF1.5%Beta1.0%Cost of Debt1.5%D/E ratio0.2WACC6.5%Valuation date2025/8/28Growth rate-1%PV of Terminal Value165,444.8PV of Free Cash Flow71,189.5Enterprise Value236,634.2+ Cash34,193.6- Minority interest- Debt(57,727.0)Equity Value213,100.8Shares Outstanding89.9Fair Value (¥)2,400",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "ca57c7fa54e54703",
      "text": "Source: Company info, Jefferies",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "d314f0a22541a89e",
      "text": "The upcoming catalysts includes:",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "283e3666ad123828",
      "text": "1. Presentation of Ph1 data for EP4 agonist in solid tumor in ESMO in October  \n2. Ph1 data announcement for NBI-567 (M1-preferring agonist), NBI-569 (M4-preferring agonist), and NBI-570 (M1/M4 dual agonist) by Neurocrine in 2HCY25  \n3. Ph1 data readout of ORX142 for sleep disorders by Centessa in 2HCY25  \n4. Ph2 data readout of ORX750 for sleep disorders by Centessa in 2HCY25  \n5. Ph2 data readout of TMP-301 for alcoholism in 2HCY25 or 1HCY26  \n6. Potential €60mn ( \\(\\sim\\) ¥10bn) receipt from BI on option execution for GPR52 agonist in 4QCY25 or 1QCY26",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "4a0b6e313f7a6564",
      "text": "Exhibit 21-Nxera CNS pipeline",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3d505323a10d6106",
      "text": "PartnerProgramIndicationPh1Ph2Ph3NeurocrineNBI-568 (M4 ago)SchizophreniaCompletion in 2027Bipolar disorderNBI-570 (M1/M4 ago)Schizophrenia CNS indicationsData readout in 2025Start in 2025NBI-567 (M1 pref ago)CNS indicationsData readout in 2025NBI-569 (M4 pref ago)CNS indicationsData readout in 2025CentesaORX750 (OX2 ago)NT1, NT2 and IHData readout in 2025ORX142 (OX2 ago)Neurological and neurodegenerative disordersData readout in 2025ORX489 (OX2 ago)Neuropsychiatric disordersBoehringer Ingelheim (opt)NXE&#x27;149 (GPR52 ago)SchizophreniaOption execution in 2025Tempero BioTMP-301 (mGlu5 NAM)Alcohol Use DisorderData readout in 2025Cocaine Use DisorderData readout in 2025",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "ae9aebc200c12e5e",
      "text": "Source: Company info., Jefferies Note: Catalysts anticipated in 2025 are shown in red.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3b7ae9c3e60a96a4",
      "text": "Exhibit 22-Nxera PL (mn)",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "6f89170b2d451a18",
      "text": "FY12/24AFY12/25EFY12/26EFY12/27EFY12/28EFY12/29ESales28,83538,13240,21347,33643,41847,136YoY%-32.2%5.5%17.7%-8.3%8.6%Cost of sales(7,616)(6,869)(7,859)(8,918)(9,563)(9,865)Gross profit21,21931,26332,35438,41833,85537,271YoY%-47.3%3.5%18.7%-11.9%10.1%Margin %73.6%82.0%80.5%81.2%78.0%79.1%SG&amp;amp;A ex R&amp;amp;D expenses(16,015)(16,000)(15,500)(15,000)(15,300)(15,453)R&amp;amp;D expenses(11,816)(13,000)(13,000)(13,000)(13.300)(13,566)Other operating income and expense1,189-----Operating income(5,423)2,2633,85410,4185,2558,252YoY%--141.7%70.3%170.3%-49.6%57.0%Margin %-18.8%5.9%9.6%22.0%12.1%17.5%Financial income1,5441,5441,5441,5441,5541,544Financial expense(783)(783)(783)(783)(783(783)Equity in earnings of affiliates------Income before income taxes(4,662)3,0244,61511,1796,0169,013Total income taxes(176)(605)(923)(2,236)(1,203)(1,803)Net income(4,838)2,4193,6928,9434,8137,210Net income attributable to non-controlling interests------Net income attributable to owners of the parent(4,838)2,4193,6928,9434,8137,210YoY%---52.6%142.2%-46.2%Margin %-16.8%6.3%9.2%18.9%11.1%15.3%EPS(54)2741994967YoY%--52.6%142.2%-51.1%37.3%",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "dac5353feca0fa59",
      "text": "Source: Company info., Jefferies",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "6031e76341520069",
      "text": "Exhibit 23-Nxera BS (mn)",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "04d9630a3bb255fc",
      "text": "FY12/24AFY12/25EFY12/26EFY12/27EFY12/28EFY12/29ETotal assets151,498147,260146,144150,044149,518151,144Total current assets57,85555,81756,80162,70164,07567,501Cash and equivalents36,20334,19431,76634,68734,21835,945Notes and accounts receivable6,6958,0559,15110,36511,13312,328Inventory8,8387,4499,76511,53012,60613,109Other6,1196,1196,1196,1196,1996,119Total fixed assets93,64391,44389,34387,34385,44383,643Total property and equipment7,4687,0686,7686,5686,4686,468Total intangible assets77,60475,80474,00472,20470,40468,604Total investments and other non-current assets8,5718,5718,5718,5718,5778,571Total liabilities and total net assets151,498147,260146,144150,044149,518151,144Total liabilities82,98076,32271,51566,47161,13255,548Total current liabilities15,63214,77415,76716,52316,98414,300Notes and accounts payable4,0523,1924,1854,9415,4025,618Short term debt5,7985,8005,8005,8005,8002,900Other5,7825,7825,7825,7825,7925,782Total long-term liabilities67,34861,54855,74849,94844,14841,248Long-term debt57,72751,92746,12740,32734,52731,627Other9,6219,6219,6219,6219,6299,621Total net assets68,51870,93774,62983,57388,38595,596Total shareholders&#x27; equity61,30163,72067,41276,35681,16888,379Non-controlling interests------Other7,2177,2177,2177,2177,2277,217",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "05948b07ecfa121d",
      "text": "Source: Company info., Jefferies",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "946ca82408937bb5",
      "text": "Exhibit 24-Nxera CF (Mmn)",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "3362a4fa5c60c2fd",
      "text": "FY12/2AFY12/25EFY12/26EFY12/27EFY12/28EFY12/29ENet cash provided by / used in operating activities(7,718)5,3895,07310,5217,2309,528Net income(4,838)2,4193,6928,9434,8137,210Depreciation and amortization3,9843,8003,8003,8003,8003,900Amortization of goodwill------Decrease / increase in notes and accounts receivable(742)(1,360)(1,096)(1,214)(768)(1,195)Decrease / increase in inventory(5,935)1,389(2,316)(1,765)(1,076)(503)Increase / decrease in notes and accounts payable(487)(860)992757461216Other300-----Net cash provided by / used in investing activities(4,763)(1,600)(1,700)(1,800)(1,900)(2,000)Payments for purchase of property and equipment(526)(600)(700)(800)(900)(1,000)Purchase of intangible fixed assets(1,011)(1,000)(1,000)(1,000)(1.000)(1,000)Other(3,226)-----Net cash provided by / used in financing activities(6,854)(5,798)(5,800)(5,800)(5,800)(5.800)Proceeds from share issuance------Repayment of debt(6,852)(5,798)(35,800)(5,800)(5,800)(5,800)Cash dividends paid------Other(2)-30,000---Net increase / decrease in cash and cash equivalents(16,797)(2,009)(2,427)2,921(470)1,728Cash and cash equivalents at beginning of period49,06536,20334,19431,76634,68734,218Cash and cash equivalents at end of period32,26834,19431,76634,68734,21835,945FCF(12,481)3,7893,3738,7215,3307,528",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "208c2c3dd0b5bf64",
      "text": "Source: Company info., Jefferies",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "1574e7acc784509b",
      "text": "Nxera PharmaNxera Pharma (formerly Sosei) is a biopharma company with a GPCR- targeted structure- based drug discovery platform. Nxera has programs from discovery phase to late clinical stage in its pipeline, and is in partnership with leading pharma and biotech companies.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "ae4b6bb4eba56041",
      "text": "Valuation: We arrive at our 2,400 PT using DCF. We think that DCF is the best way to value a company such as Nxera, which is likely to experience a rapid increase in future profits.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "5e6ec97375b06752",
      "text": "Risks: Downside risks include the failure of clinical trials and Nxera's partners abandoning development of promising candidates because of changing priorities.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "e8cc00785c847406",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "ae866af4d106b793",
      "text": "August 28, 2025 9:07 A.M. August 28, 2025 9:07 A.M.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "9229a48a40770bec",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) is \\(20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "67ff1f36bbb7a839",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "fbd71495aa22f42a",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company. NC - Not covered. Jefferies does not cover this company.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "367e58c5699169e8",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "b5de757a735c6e93",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "2b05902d8bf5632f",
      "text": "Jefferies methodology for assigig ratings may include the fllowing: market capitalization, maturity, growth/val, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "e45cfe3babd32b22",
      "text": "Jefferies Franchise PicksJefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "5d2a09be82ce6305",
      "text": "Nxera Pharma (4565 JP: ¥912, BUY)",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "76424f9ce77e2788",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "0cd72dd8d1bd02a1",
      "text": "I: Initiating Coverage D: Dropped Coverage B: Buy H: Hold UP: Underperform",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "b1edde0d192cdb9c",
      "text": "Distribution of Ratings",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "f7e72c0edd891552",
      "text": "CountPercentCountPercentCountPercentBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "ae3c04096c98d58e",
      "text": "Jefries does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "fefabf437dded9b9",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "443c88ade99caeac",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "7c416355cb6d7219",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "84ec356ba2db5491",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "0d681d1c206ab372",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "08033634d00d1947",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "141ff7423769eb84",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "2f4040a74c059b35",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "1db9a7d78cb9857c",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "229472c4fe7e63aa",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "6b46ae5bc03b050c",
      "text": "whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "4277fcc1f56c10ab",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "2b964cda153e3158",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "fe7ae0f89d60593b",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "fcd7fb90de92d7b0",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "78a232781e2448a5",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "058c0a57832cf69e",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "65b39fd8d7ab52b5",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "220a427ced49fda0",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES.",
      "page": 20,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "1758c5004bf0c734",
      "name": "Alcohol Use",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "591c57eab2aa8645",
      "name": "Any TEAE",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e1ed69c5ef7a1ca4",
      "name": "Attention Deficit",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c9cbcaf17ced802e",
      "name": "Biotechnology Nxera",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5d012cfae6e8b67d",
      "name": "Boehringer Ingelheim",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cb912f2c6b1af03d",
      "name": "Business Model",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c6dab967476b951c",
      "name": "Buy\n\nWe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "86aca653c3ded4aa",
      "name": "Clinical Trials",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "68bdae89d2775da3",
      "name": "Cocaine Use",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a92ba89b9eff6c1b",
      "name": "Company Target",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a82757501273b566",
      "name": "Differ\n\nNxera",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e736f0c0f1f7561e",
      "name": "Disclosures\n\nJefries",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bb6342a62eb227ed",
      "name": "Discount Factor",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "combo",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 500,
              "max": 5500
            }
          }
        },
        "series": [
          {
            "name": "Historical Data",
            "unit": null,
            "values": [
              {
                "x": "2024",
                "y": 1500
              },
              {
                "x": "2025",
                "y": 900
              }
            ]
          },
          {
            "name": "Current Point",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 900
              }
            ]
          },
          {
            "name": "Upside Forecast",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 900
              },
              {
                "x": "+12 mo.",
                "y": 5400
              }
            ]
          },
          {
            "name": "Mid Forecast",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 900
              },
              {
                "x": "+12 mo.",
                "y": 2400
              }
            ]
          },
          {
            "name": "Downside Forecast",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 900
              },
              {
                "x": "+12 mo.",
                "y": 600
              }
            ]
          }
        ],
        "figure_id": "84f02fc8726086a7",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "other",
        "title": "Report",
        "page": 2,
        "axes": null,
        "series": [],
        "figure_id": "016085a277c57d96",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "0",
              "1",
              "2",
              "3",
              "4",
              "5",
              "6"
            ]
          },
          "y": {
            "unit": "PANSS score change from BL",
            "range": {
              "min": -25,
              "max": 0
            }
          }
        },
        "series": [
          {
            "name": "Placebo",
            "unit": "PANSS score change from BL",
            "values": [
              0,
              -5.7,
              -8.2,
              -7.7,
              -9.6,
              -10.2,
              -10.8
            ]
          },
          {
            "name": "NBI-568 20mg",
            "unit": "PANSS score change from BL",
            "values": [
              0,
              -8.4,
              -11.5,
              -13.4,
              -16.4,
              -20.2,
              -18.2
            ]
          }
        ],
        "figure_id": "01032ab1116a2385",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "other",
        "title": "Chemical Structure",
        "page": 5,
        "axes": null,
        "series": [
          {
            "name": "Chemical Structure",
            "unit": null,
            "values": "A chemical structure with R1, R2, R3, R4, and Q groups, featuring a piperidine ring, a spiro-fused azetidine-pyrrolidine system, and a carbamate group."
          }
        ],
        "figure_id": "c57504d531427a9d",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E",
              "FY12/35E",
              "FY12/36E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0.0,
              "max": 12.0
            }
          }
        },
        "series": [
          {
            "name": null,
            "unit": "¥bn",
            "values": [
              0.5,
              1.5,
              3.1,
              5.7,
              7.9,
              10.3,
              11.0,
              11.4
            ]
          }
        ],
        "figure_id": "db86558f96c624bd",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1.0mg",
              "2.5mg",
              "3.5mg",
              "5.0mg"
            ]
          },
          "y": {
            "unit": "min",
            "range": {
              "min": 0,
              "max": 40
            }
          }
        },
        "series": [
          {
            "name": "ORX750",
            "unit": "min",
            "values": [
              17.6,
              32,
              33.6,
              37.9
            ]
          },
          {
            "name": "Placebo",
            "unit": "min",
            "values": [
              9.5,
              16.7,
              13.4,
              15.3
            ]
          }
        ],
        "figure_id": "133f11dab4b94ede",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 8,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E",
              "FY12/35E",
              "FY12/36E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0.0,
              "max": 8.0
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "¥bn",
            "values": [
              0.4,
              1.1,
              2.2,
              3.4,
              4.6,
              5.8,
              7.1,
              7.3,
              7.6
            ]
          }
        ],
        "figure_id": "8e74d1cc04dfc8c7",
        "provenance": {
          "page": 8
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/25E",
              "FY12/26E",
              "FY12/27E",
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0.0,
              "max": 18.0
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "¥bn",
            "values": [
              13.7,
              14.6,
              15.5,
              15.5,
              15.5,
              15.5,
              14.7,
              14.0,
              13.3,
              12.6
            ]
          }
        ],
        "figure_id": "9a66049d1a4cbde9",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/25E",
              "FY12/26E",
              "FY12/27E",
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0.0,
              "max": 10.0
            }
          }
        },
        "series": [
          {
            "name": null,
            "unit": "¥bn",
            "values": [
              4.8,
              5.8,
              6.9,
              7.3,
              7.7,
              8.1,
              8.7,
              9.0,
              8.9,
              8.5
            ]
          }
        ],
        "figure_id": "7ae273ac04bb7fdd",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/25E",
              "FY12/26E",
              "FY12/27E",
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0.0,
              "max": 14.0
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "¥bn",
            "values": [
              3.6,
              5.5,
              7.6,
              9.8,
              11.9,
              12.6,
              12.6,
              12.6,
              12.6,
              12.6
            ]
          }
        ],
        "figure_id": "bbf82cc8558801b3",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/25E",
              "FY12/26E",
              "FY12/27E",
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0.0,
              "max": 7.0
            }
          }
        },
        "series": [
          {
            "name": null,
            "unit": "¥bn",
            "values": [
              0.6,
              1.1,
              2.1,
              3.3,
              4.7,
              5.7,
              6.3,
              6.3,
              6.3,
              6.3
            ]
          }
        ],
        "figure_id": "c2ef2bc7e394b65e",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "combo",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/24A",
              "FY12/25E",
              "FY12/26E",
              "FY12/27E",
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0.0,
              "max": 35.0
            }
          }
        },
        "series": [
          {
            "name": "Core operating costs (LHS)",
            "unit": "¥bn",
            "values": [
              27.8,
              29.0,
              28.5,
              28.0,
              28.6,
              29.0,
              29.3,
              29.6,
              29.9,
              30.2,
              30.5
            ]
          },
          {
            "name": "Operating cost ratio (RHS)",
            "unit": "%",
            "values": [
              96.5,
              76.1,
              70.9,
              59.2,
              65.9,
              61.6,
              60.3,
              55.1,
              51.5,
              48.7,
              45.4
            ]
          }
        ],
        "figure_id": "b4a51cf567710220",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/24A",
              "FY12/25E",
              "FY12/26E",
              "FY12/27E",
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": 0,
              "max": 80
            }
          }
        },
        "series": [
          {
            "name": "Product sales *incl. royalty",
            "unit": "¥bn",
            "values": [
              16.0,
              20.0,
              22.0,
              25.0,
              27.0,
              30.0,
              32.0,
              36.0,
              40.0,
              45.0,
              50.0
            ]
          },
          {
            "name": "Milestone income",
            "unit": "¥bn",
            "values": [
              9.0,
              14.0,
              9.0,
              14.0,
              10.0,
              10.0,
              9.0,
              10.0,
              12.0,
              12.0,
              10.0
            ]
          },
          {
            "name": "Upfront fee",
            "unit": "¥bn",
            "values": [
              2.0,
              3.0,
              6.0,
              6.0,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0
            ]
          },
          {
            "name": "Transfer of deferred income",
            "unit": "¥bn",
            "values": [
              1.8,
              1.1,
              3.2,
              2.3,
              1.4,
              2.1,
              2.6,
              2.7,
              1.0,
              0.0,
              2.1
            ]
          },
          {
            "name": "Others",
            "unit": "¥bn",
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        ],
        "figure_id": "0d9dd99fc88ef3a7",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY12/24A",
              "FY12/25E",
              "FY12/26E",
              "FY12/27E",
              "FY12/28E",
              "FY12/29E",
              "FY12/30E",
              "FY12/31E",
              "FY12/32E",
              "FY12/33E",
              "FY12/34E"
            ]
          },
          "y": {
            "unit": "¥bn",
            "range": {
              "min": -10.0,
              "max": 35.0
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "¥bn",
            "values": [
              -5.4,
              2.3,
              3.9,
              10.4,
              5.3,
              8.3,
              9.9,
              15.7,
              19.9,
              23.6,
              28.5
            ]
          }
        ],
        "figure_id": "599f7e2a74e7151b",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Nxera Pharma (4565 JP) as of 08-27-2025",
        "page": 17,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "¥",
            "range": {
              "min": 500,
              "max": 3500
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "¥",
            "values": [
              {
                "date": "2022-10",
                "value": 1800
              },
              {
                "date": "2023-03-06",
                "value": 4200
              },
              {
                "date": "2023-06-27",
                "value": 1800
              },
              {
                "date": "2023-11-13",
                "value": 1900
              },
              {
                "date": "2023-11-29",
                "value": 1600
              },
              {
                "date": "2023-11-29",
                "value": 1700
              },
              {
                "date": "2024-01-24",
                "value": 1800
              },
              {
                "date": "2024-03-11",
                "value": 2100
              },
              {
                "date": "2025-03-11",
                "value": 2000
              }
            ]
          }
        ],
        "figure_id": "a8b8619bd7d9ef09",
        "provenance": {
          "page": 17
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "9bc102c9325d1ee4",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tential reduction in COGS for Quviviq sales, raising the gross margin assumption at peak sales from 30% to 40%. As a result, we revise our 10y DCF- based target price from ¥2,000 to ¥2,400. As we beli",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "129e268f0ba5dfa0",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "reduction in COGS for Quviviq sales, raising the gross margin assumption at peak sales from 30% to 40%. As a result, we revise our 10y DCF- based target price from ¥2,000 to ¥2,400. As we believe the ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c4ff72c3c8e7ceb8",
        "value": 1.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>PRICE</td><td>¥912*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>↑¥2,400 (¥2,000) + 163%</td></tr><tr><td>52W HIGH-LOW</td><td>¥1,500 - ¥668</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7b9111b1571f621e",
        "value": 0.8220000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>52W HIGH-LOW</td><td>¥1,500 - ¥668</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>82.2% | 4.96</td></tr><tr><td>MARKET CAP</td><td>¥82.08 | $554.3M</td></tr><tr><td>TICKER</td><td>45",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a7281af13ff3fa81",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td></td><td>2025</td><td>2026</td><td>2025</td><td>2026</td><td></td></tr><tr><td>REV</td><td>+3%</td><td>+12%</td><td>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f65543f50b80392f",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2025</td><td>2026</td><td>2025</td><td>2026</td><td></td></tr><tr><td>REV</td><td>+3%</td><td>+12%</td><td>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</td><td>+4,63",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "89bd0c87ed332703",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2026</td><td>2025</td><td>2026</td><td></td></tr><tr><td>REV</td><td>+3%</td><td>+12%</td><td>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</td><td>+4,635%</td><td>-1",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e9c64ad4d4644015",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2025</td><td>2026</td><td></td></tr><tr><td>REV</td><td>+3%</td><td>+12%</td><td>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</td><td>+4,635%</td><td>-10%</td><td></",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a5da0db478974927",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>REV</td><td>+3%</td><td>+12%</td><td>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</td><td>+4,635%</td><td>-10%</td><td></td></tr><tr><td></td><td></td><td></td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "de72bc044139b761",
        "value": 1.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>+3%</td><td>+12%</td><td>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</td><td>+4,635%</td><td>-10%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "70d3dbf8a4bd3c28",
        "value": 6.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>+12%</td><td>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</td><td>+4,635%</td><td>-10%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a4fa1bac7be7e123",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>+12%</td><td>-1%</td><td></td></tr><tr><td>EPS</td><td>-24%</td><td>+197%</td><td>+4,635%</td><td>-10%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2025 (",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "90b2d245aac2e521",
        "value": 2400.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "cal sales business, and 3) potential for cost efficiency improvements. We raise our target price to ¥2,400 and reiterate our Buy rating. Abundant opportunities in CNS area. Nxera has impressive track ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a50192469b6c03aa",
        "value": 3.3,
        "unit": "¥",
        "metric_type": "currency",
        "context": "ecord. Domestic business could be a cash generator. Nxera has already achieved positive core OP of ¥3.3bn in its domestic business in 1H FY25, driven by sales of Pivlaz. With continued growth of Quviv",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "fb3421ce71edda68",
        "value": 10.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "With continued growth of Quviviq, we estimate that annual CF from the domestic segment could exceed ¥10bn in three years. Nxera is currently repaying debt from the Idorsia acquisition at a pace of \\(\\",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ddf385080675b81b",
        "value": 6.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "in three years. Nxera is currently repaying debt from the Idorsia acquisition at a pace of \\(\\sim\\) ¥6bn per year, which can be fully covered by domestic CF. Once the debt is repaid, this CF can be re",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "66cb7f34403e9648",
        "value": 28.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "tes without increasing debt. Room for cost efficiency improvements. Nxera's SG&A and R&D expenses (¥28bn in FY24) appear relatively high compared to peers with similar platform- based business models.",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "dbd74e0115a2f194",
        "value": 2000.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "sumption at peak sales from 30% to 40%. As a result, we revise our 10y DCF- based target price from ¥2,000 to ¥2,400. As we believe the upcoming catalysts include low risk positive catalysts, this cou",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "45ad7b4c4f920dc2",
        "value": 2400.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "t peak sales from 30% to 40%. As a result, we revise our 10y DCF- based target price from ¥2,000 to ¥2,400. As we believe the upcoming catalysts include low risk positive catalysts, this could be a gr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ba96b0888a32bc44",
        "value": 912.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "pan=\"2\">TARGET | ESTIMATE CHANGE</td></tr><tr><td>RATING</td><td>BUY</td></tr><tr><td>PRICE</td><td>¥912*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>↑¥2,400 (¥2,000) + 163%</td></tr><tr><td>52W H",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0d014cc8686b6b42",
        "value": 2400.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "G</td><td>BUY</td></tr><tr><td>PRICE</td><td>¥912*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>↑¥2,400 (¥2,000) + 163%</td></tr><tr><td>52W HIGH-LOW</td><td>¥1,500 - ¥668</td></tr><tr><td>FLOAT (%",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "940a9de5dfd15187",
        "value": 2000.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "d>BUY</td></tr><tr><td>PRICE</td><td>¥912*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>↑¥2,400 (¥2,000) + 163%</td></tr><tr><td>52W HIGH-LOW</td><td>¥1,500 - ¥668</td></tr><tr><td>FLOAT (%) | ADV ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3be16fee25bfd20a",
        "value": 1500.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "tr><td>PRICE TARGET | % TO PT</td><td>↑¥2,400 (¥2,000) + 163%</td></tr><tr><td>52W HIGH-LOW</td><td>¥1,500 - ¥668</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>82.2% | 4.96</td></tr><tr><td>MARKET",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5c8573a93c1a815f",
        "value": 668.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "ICE TARGET | % TO PT</td><td>↑¥2,400 (¥2,000) + 163%</td></tr><tr><td>52W HIGH-LOW</td><td>¥1,500 - ¥668</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>82.2% | 4.96</td></tr><tr><td>MARKET CAP</td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "cf5ecd133a033589",
        "value": 82.08,
        "unit": "¥",
        "metric_type": "currency",
        "context": "</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>82.2% | 4.96</td></tr><tr><td>MARKET CAP</td><td>¥82.08 | $554.3M</td></tr><tr><td>TICKER</td><td>4565 JP</td></tr></table> \\*Prior trading day's clo",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "cc23870e024182c6",
        "value": 554300000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><tr><td>FLOAT (%) | ADV MM (USD)</td><td>82.2% | 4.96</td></tr><tr><td>MARKET CAP</td><td>¥82.08 | $554.3M</td></tr><tr><td>TICKER</td><td>4565 JP</td></tr></table> \\*Prior trading day's closing pric",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f4e5c0a4d56ea1ee",
        "value": 26.91,
        "unit": "¥",
        "metric_type": "currency",
        "context": "<td>Q3</td><td>Q4</td><td>FY12</td></tr><tr><td>EPS</td><td>-</td><td>-</td><td>-</td><td>-</td><td>¥26.91</td></tr><tr><td>PREV</td><td></td><td></td><td></td><td></td><td>35.42</td></tr></table> Exh",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3b8d9c640c50caa1",
        "value": 1.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s. ![Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> Base Case, ￥2400, +163% Base case PT of ¥2,400 is based on 10- year DCF through FY12/34. Upside Scenario, ￥5400, +492% B",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "fbde6ab1d8ce7482",
        "value": 4.92,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0, +163% Base case PT of ¥2,400 is based on 10- year DCF through FY12/34. Upside Scenario, ￥5400, +492% Best case PT of ¥5,400 is based on 10- year DCF through FY12/34 and 20% PoS for Pfizer's GLP- 1 ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "9214ac158463f50d",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Upside Scenario, ￥5400, +492% Best case PT of ¥5,400 is based on 10- year DCF through FY12/34 and 20% PoS for Pfizer's GLP- 1 drug, which is licensed from Nxera. Downside Scenario, ￥600, - 34% Worst",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "8b61d127562406d8",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/34 and 20% PoS for Pfizer's GLP- 1 drug, which is licensed from Nxera. Downside Scenario, ￥600, - 34% Worst case PT of ¥1,000 is based on 10- year DCF through FY12/34 and failure of Neurocrine's M4 a",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "384ee39f091a8b23",
        "value": 2400.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "s/1_0.jpg) <center>Risk/Reward - 12 Month View </center> Base Case, ￥2400, +163% Base case PT of ¥2,400 is based on 10- year DCF through FY12/34. Upside Scenario, ￥5400, +492% Best case PT of ¥5,400 i",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "5bff1b90aa0b9434",
        "value": 5400.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "of ¥2,400 is based on 10- year DCF through FY12/34. Upside Scenario, ￥5400, +492% Best case PT of ¥5,400 is based on 10- year DCF through FY12/34 and 20% PoS for Pfizer's GLP- 1 drug, which is license",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "345ba1c86a18130d",
        "value": 1000.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "izer's GLP- 1 drug, which is licensed from Nxera. Downside Scenario, ￥600, - 34% Worst case PT of ¥1,000 is based on 10- year DCF through FY12/34 and failure of Neurocrine's M4 agonist, which are lice",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "78b1901a4db1a099",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>NBI-568 (20mg)</td><td>Placebo</td><td>Cobenfy</td><td>Placebo</td></tr><tr><td>Nausea</td><td>5%</td><td>3%</td><td>19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d0748025fbba5aeb",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8 (20mg)</td><td>Placebo</td><td>Cobenfy</td><td>Placebo</td></tr><tr><td>Nausea</td><td>5%</td><td>3%</td><td>19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>1",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "46ee7d4b87e8ea89",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Placebo</td><td>Cobenfy</td><td>Placebo</td></tr><tr><td>Nausea</td><td>5%</td><td>3%</td><td>19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ba1cf433413bcb2b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "o</td><td>Cobenfy</td><td>Placebo</td></tr><tr><td>Nausea</td><td>5%</td><td>3%</td><td>19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "84662636302ad12e",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Nausea</td><td>5%</td><td>3%</td><td>19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7e5ce1f59b10fb12",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">5%</td><td>3%</td><td>19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1c1a1f21f7473bc5",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">3%</td><td>19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%</td></tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "aeb63589cb335e3c",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "19%</td><td>4%</td></tr><tr><td>Dyspepsia</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitt",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "10a85daa982d2a7b",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "a</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4176c100f5d5cd8a",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "amp;lt;5%</td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>1",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7ab28063b49890d5",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&amp;lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>15%</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1c1c7177a1990f23",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lt;5%</td><td>18%</td><td>5%</td></tr><tr><td>Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>15%</td><td>1%</td></tr>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b2f2b049499488e1",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Costipation</td><td>5%</td><td>3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>15%</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "82d81ffc3c49f88b",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">5%</td><td>3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>15%</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9b33e0a7f2e66eae",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">3%</td><td>17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>15%</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "afa9ccc9bf99d74b",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "17%</td><td>7%</td></tr><tr><td>Vomitting</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>15%</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9aa519ee7e3c64b1",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">&amp;lt;5%</td><td>&amp;lt;5%</td><td>15%</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7f5c4dde5cfb2439",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">&amp;lt;5%</td><td>15%</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f50f03c626915e41",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>15%</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "80302b26dddcfa5a",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1%</td></tr><tr><td>Hypertension</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizzine",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5bbd31aec73e79a0",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "on</td><td>&amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4176c100f5d5cd8a",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "amp;lt;5%</td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "31956a85dc153936",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&amp;lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "06a76f86cb21e069",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";lt;5%</td><td>11%</td><td>2%</td></tr><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "860f99b962a992e6",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Somnolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;l",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c2315cd8e7ad20f8",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nolence</td><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;lt;2%</td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d2c1d8041edfa4f5",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>13%</td><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;lt;2%</td><td>&amp;lt;2%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2ed04d2a3449cba7",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>3%</td><td>3%</td><td>2%</td></tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;lt;2%</td><td>&amp;lt;2%</td></tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2112a443720f81c6",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;lt;2%</td><td>&amp;lt;2%</td></tr></table> Source: Company info, Cobenfy",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "357bb4c30dd1a7bd",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Dizziness</td><td>13%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;lt;2%</td><td>&amp;lt;2%</td></tr></table> Source: Company info, Cobenfy package in",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fa98c6dbfa1b9533",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>1%</td><td>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;lt;2%</td><td>&amp;lt;2%</td></tr></table> Source: Company info, Cobenfy package insert ## Huge potenti",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ada0f8e1dbdd06b1",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5%</td><td>2%</td></tr><tr><td>Headache</td><td>3%</td><td>20%</td><td>&amp;lt;2%</td><td>&amp;lt;2%</td></tr></table> Source: Company info, Cobenfy package insert ## Huge potential in NBI-567, NBI-",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fa958dfafaa9636c",
        "value": 700.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "assumption is a combined unadjusted peak sales potential of ¥700bn across the four compounds, to which we apply a weighted average PoS of \\(13\\%\\) in FY12/36. Regar",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a8e5ee8f61c6d24a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".0mg (N=8)</td><td>ORX750 4.0mg (N=8)</td></tr><tr><td>TEAEs leading to discontinuation (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "664e864450fdd696",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>ORX750 4.0mg (N=8)</td></tr><tr><td>TEAEs leading to discontinuation (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "50e04534cafe85a7",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "750 4.0mg (N=8)</td></tr><tr><td>TEAEs leading to discontinuation (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Seri",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "cbb9c7ea1dfaefbb",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "N=8)</td></tr><tr><td>TEAEs leading to discontinuation (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "b9681444ab41fea8",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>TEAEs leading to discontinuation (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a542ee880efa9bcc",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ing to discontinuation (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "9b2bf55a009d3b10",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ontinuation (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "dea78a93a8e9d0d1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d6d09711e2b7ebb9",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "33ba58b59ae513b0",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "4c078ee0b46b30ea",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "32aa4ecc25aa37e1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any ",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "3a0fe386f0b4ead7",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>0%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "87a8bc4e0d097d51",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>0%</td></tr><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "102322858d6df46f",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Serious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fc0bb6364a5529f6",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rious TEAEs (%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>1",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "dea78a93a8e9d0d1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(%)</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d6d09711e2b7ebb9",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1eb81ea0cbbce16d",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "49c20fa489927fff",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>0</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7567cfe37a19e824",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></ta",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0d4cd6c1395e7f03",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0%</td><td>0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></table> Source:",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "b66040aa7bec83f3",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></table> Source: Company inf",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "78c14b89af68ca0b",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td></tr><tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></table> Source: Company info. In the P",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "469aafb373ce2075",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Any TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></table> Source: Company info. In the Ph2a trial, e",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1394a4548556ff5f",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "TEAE (%)</td><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></table> Source: Company info. In the Ph2a trial, efficacy will",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "8f5aa1f72c4fd5c2",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>27%</td><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></table> Source: Company info. In the Ph2a trial, efficacy will be assessed",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c40c251c61e9343f",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>33%</td><td>33%</td><td>11%</td><td>0%</td><td>33%</td><td>50%</td><td>50%</td><td>50%</td><td>75%</td></tr></table> Source: Company info. In the Ph2a trial, efficacy will be assessed as a second",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "4b0860894cb47db5",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e estimate total franchise sales to reach approximately ¥800bn, and apply a weighted average PoS of 30%. Based on these assumptions, we project royalty income to Nxera of ¥8bn in FY12/36. ORX750 showe",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "93117dc6ca1eb0f2",
        "value": 800.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "n sales of these OX2R franchise compounds. We estimate total franchise sales to reach approximately ¥800bn, and apply a weighted average PoS of 30%. Based on these assumptions, we project royalty inco",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fd5b05be48a866fa",
        "value": 8.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "ly a weighted average PoS of 30%. Based on these assumptions, we project royalty income to Nxera of ¥8bn in FY12/36. ORX750 showed positive safety profile ORX142 and ORX489 has higher selectivity and",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0a3e2b73cf068d91",
        "value": 25.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "tion- to- license agreement with Boehringer Ingelheim. Under the terms of the deal, Boehringer paid €25mn upfront and holds an exclusive option to license the program upon completion of the ongoing Ph",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "1efe2888e18371b0",
        "value": 60.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "es. If Boehringer exercises the option within this year, Nxera is expected to receive an additional €60mn (approximately ¥10bn), which could bring the company's consolidated earnings into positive ter",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b15bb7d786b83c81",
        "value": 10.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "rcises the option within this year, Nxera is expected to receive an additional €60mn (approximately ¥10bn), which could bring the company's consolidated earnings into positive territory. Currently we ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "12b13abbdcec4b96",
        "value": 30.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "with a baseline goal of abstinence). We estimate peak sales for TMP- 301 in alcohol use disorder at ¥30 billion. However, with an estimated 28mn patients in the U.S. alone, the upside could be signifi",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b26240ec6048f318",
        "value": 6.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "supply. On a cash flow basis, we estimate ¥6.0bn. Given that Quvivig's patent extends through 2038, we expect a longer duration of cash flow contr",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "91bd608f5d3992fd",
        "value": 30.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "s estimates </center> ## Cashflow decreases leverage risk As of the end of June 2025, Nxera holds ¥30.0 bn in borrowings and ¥31.0 bn in convertible bonds. We believe abundant cash flow from Pivlaz an",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "4386f94358ef8b9a",
        "value": 31.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "ashflow decreases leverage risk As of the end of June 2025, Nxera holds ¥30.0 bn in borrowings and ¥31.0 bn in convertible bonds. We believe abundant cash flow from Pivlaz and Quvivig decreases the ri",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "0a31203e645c9615",
        "value": 30.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "undant cash flow from Pivlaz and Quvivig decreases the risk associated with financial leverage. The ¥30.0 bn in borrowings is related to the acquisition of Idorsia. Nxera plans to repay approximately ",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "6166c2a365a073e9",
        "value": 6.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "¥30.0 bn in borrowings is related to the acquisition of Idorsia. Nxera plans to repay approximately ¥6.0 bn annually through June 2030. This repayment amount can be covered by cash flow generated from",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "880d8acc9bca10ad",
        "value": 32.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "ition will begin to materialize from next fiscal year in terms of cash flow. Nxera currently holds ¥32.0 bn in convertible bonds (CB) with a strike price of ¥1,782 and maturity in 2028. We view this a",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "989886ed75bddbf2",
        "value": 1782.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "erms of cash flow. Nxera currently holds ¥32.0 bn in convertible bonds (CB) with a strike price of ¥1,782 and maturity in 2028. We view this as an appropriate level of leverage to efficiently operate ",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "fd86821ef208a9f1",
        "value": 28.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "ugh clause amendments or refinancing. ## Potential to reduce costs Nxera's SG&A and R&D expenses (¥28bn in FY24) appear relatively high compared to peers with similar platform- based business models. ",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "5f2091d7b7ac6f04",
        "value": 0.075,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>9,396</td><td>9,914</td><td>11,206</td><td>12,534</td></tr><tr><td>Cost of Equity</td><td>7.5%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "cb62c3ef2cd2b20c",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ERP</td><td>6.0%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "34fddf0e5ef51d73",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>RF</td><td>1.5%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "b737eda06591c265",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Beta</td><td>1.0%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "4d43e929abf14951",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cost of Debt</td><td>1.5%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "a0fad88f7e22abc6",
        "value": 0.065,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WACC</td><td>6.5%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "9225fab382d9d1a8",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Growth rate</td><td>-1%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "fc3e100187be3ade",
        "value": 60.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "ntessa in 2HCY25 5. Ph2 data readout of TMP-301 for alcoholism in 2HCY25 or 1HCY26 6. Potential €60mn ( \\(\\sim\\) ¥10bn) receipt from BI on option execution for GPR52 agonist in 4QCY25 or 1QCY26<｜end▁",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "4fcf271d86ab2129",
        "value": 10.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "5. Ph2 data readout of TMP-301 for alcoholism in 2HCY25 or 1HCY26 6. Potential €60mn ( \\(\\sim\\) ¥10bn) receipt from BI on option execution for GPR52 agonist in 4QCY25 or 1QCY26<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "fbd644cb53c2e590",
        "value": 0.322,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>40,213</td><td>47,336</td><td>43,418</td><td>47,136</td></tr><tr><td>YoY%</td><td>-</td><td>32.2%</td><td>5.5%</td><td>17.7%</td><td>-8.3%</td><td>8.6%</td></tr><tr><td>Cost of sales</td><td>(",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "296ec7ee25147a50",
        "value": 0.055,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>47,336</td><td>43,418</td><td>47,136</td></tr><tr><td>YoY%</td><td>-</td><td>32.2%</td><td>5.5%</td><td>17.7%</td><td>-8.3%</td><td>8.6%</td></tr><tr><td>Cost of sales</td><td>(7,616)</td><td",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "a750a67f84e3c002",
        "value": 0.177,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36</td><td>43,418</td><td>47,136</td></tr><tr><td>YoY%</td><td>-</td><td>32.2%</td><td>5.5%</td><td>17.7%</td><td>-8.3%</td><td>8.6%</td></tr><tr><td>Cost of sales</td><td>(7,616)</td><td>(6,869)</td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "e3219572b1384ae7",
        "value": -0.083,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "418</td><td>47,136</td></tr><tr><td>YoY%</td><td>-</td><td>32.2%</td><td>5.5%</td><td>17.7%</td><td>-8.3%</td><td>8.6%</td></tr><tr><td>Cost of sales</td><td>(7,616)</td><td>(6,869)</td><td>(7,859)</t",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "496c85672b0e1ed1",
        "value": 0.086,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",136</td></tr><tr><td>YoY%</td><td>-</td><td>32.2%</td><td>5.5%</td><td>17.7%</td><td>-8.3%</td><td>8.6%</td></tr><tr><td>Cost of sales</td><td>(7,616)</td><td>(6,869)</td><td>(7,859)</td><td>(8,918)<",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "8e776802bf651bac",
        "value": 0.473,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>32,354</td><td>38,418</td><td>33,855</td><td>37,271</td></tr><tr><td>YoY%</td><td>-</td><td>47.3%</td><td>3.5%</td><td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "f336d2cbc7d4ab05",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>38,418</td><td>33,855</td><td>37,271</td></tr><tr><td>YoY%</td><td>-</td><td>47.3%</td><td>3.5%</td><td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "12383039fd76d5c8",
        "value": 0.187,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "18</td><td>33,855</td><td>37,271</td></tr><tr><td>YoY%</td><td>-</td><td>47.3%</td><td>3.5%</td><td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "472a1e8b685549fe",
        "value": -0.11900000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "855</td><td>37,271</td></tr><tr><td>YoY%</td><td>-</td><td>47.3%</td><td>3.5%</td><td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "f42ca95e67794b69",
        "value": 0.10099999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "271</td></tr><tr><td>YoY%</td><td>-</td><td>47.3%</td><td>3.5%</td><td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.2%</td><td>78.0",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "6f09f2922b9f9b49",
        "value": 0.736,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>47.3%</td><td>3.5%</td><td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.2%</td><td>78.0%</td><td>79.1%</td></tr><tr><td>SG&amp;",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "2ad0cc203af551a6",
        "value": 0.82,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>3.5%</td><td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.2%</td><td>78.0%</td><td>79.1%</td></tr><tr><td>SG&amp;amp;A ex R&amp",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "db50e84154367fc4",
        "value": 0.805,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>18.7%</td><td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.2%</td><td>78.0%</td><td>79.1%</td></tr><tr><td>SG&amp;amp;A ex R&amp;amp;D expense",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "8a2c5039a1dcae2f",
        "value": 0.812,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-11.9%</td><td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.2%</td><td>78.0%</td><td>79.1%</td></tr><tr><td>SG&amp;amp;A ex R&amp;amp;D expenses</td><td>(16,",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "2a0a8cb9e1a0bc85",
        "value": 0.78,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>10.1%</td></tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.2%</td><td>78.0%</td><td>79.1%</td></tr><tr><td>SG&amp;amp;A ex R&amp;amp;D expenses</td><td>(16,015)</td><td>(",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "e5574aa576f45d5e",
        "value": 0.7909999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Margin %</td><td>73.6%</td><td>82.0%</td><td>80.5%</td><td>81.2%</td><td>78.0%</td><td>79.1%</td></tr><tr><td>SG&amp;amp;A ex R&amp;amp;D expenses</td><td>(16,015)</td><td>(16,000)</td><t",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "023af21a2de3c9a0",
        "value": -1.4169999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "63</td><td>3,854</td><td>10,418</td><td>5,255</td><td>8,252</td></tr><tr><td>YoY%</td><td>-</td><td>-141.7%</td><td>70.3%</td><td>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "502f48ec685948d4",
        "value": 0.703,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>10,418</td><td>5,255</td><td>8,252</td></tr><tr><td>YoY%</td><td>-</td><td>-141.7%</td><td>70.3%</td><td>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "2b81d9ff90e36111",
        "value": 1.703,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>5,255</td><td>8,252</td></tr><tr><td>YoY%</td><td>-</td><td>-141.7%</td><td>70.3%</td><td>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "30f1868d3610dde6",
        "value": -0.496,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>8,252</td></tr><tr><td>YoY%</td><td>-</td><td>-141.7%</td><td>70.3%</td><td>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "70f32bb66dfb825a",
        "value": 0.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>YoY%</td><td>-</td><td>-141.7%</td><td>70.3%</td><td>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0%</td><td>12.1%",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "ccf90ce9856bd76d",
        "value": -0.188,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-141.7%</td><td>70.3%</td><td>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0%</td><td>12.1%</td><td>17.5%</td></tr><tr><td>Financia",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "1af7f04978ac8753",
        "value": 0.059000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">70.3%</td><td>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0%</td><td>12.1%</td><td>17.5%</td></tr><tr><td>Financial income</td><t",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "7cf2357b401d8494",
        "value": 0.096,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>170.3%</td><td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0%</td><td>12.1%</td><td>17.5%</td></tr><tr><td>Financial income</td><td>1,544</td><",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "a4c034dc1611b3c6",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-49.6%</td><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0%</td><td>12.1%</td><td>17.5%</td></tr><tr><td>Financial income</td><td>1,544</td><td>1,544</td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "0ae4668c2375dc93",
        "value": 0.121,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>57.0%</td></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0%</td><td>12.1%</td><td>17.5%</td></tr><tr><td>Financial income</td><td>1,544</td><td>1,544</td><td>1,544</td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "e2cdbeaa91d10256",
        "value": 0.175,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Margin %</td><td>-18.8%</td><td>5.9%</td><td>9.6%</td><td>22.0%</td><td>12.1%</td><td>17.5%</td></tr><tr><td>Financial income</td><td>1,544</td><td>1,544</td><td>1,544</td><td>1,544</td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "cc0cd8b5172f06ca",
        "value": 0.526,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>8,943</td><td>4,813</td><td>7,210</td></tr><tr><td>YoY%</td><td>-</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "d8cddd78fc3d94f0",
        "value": 1.422,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>4,813</td><td>7,210</td></tr><tr><td>YoY%</td><td>-</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "f98fff9ae6e01a12",
        "value": -0.462,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>7,210</td></tr><tr><td>YoY%</td><td>-</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.9%</td><td>11.1",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "4f4096aa8e5b4664",
        "value": -0.168,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.9%</td><td>11.1%</td><td>15.3%</td></tr><tr><td>EPS</td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "5d4ac967a2853dff",
        "value": 0.063,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-</td><td>52.6%</td><td>142.2%</td><td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.9%</td><td>11.1%</td><td>15.3%</td></tr><tr><td>EPS</td><td>(54)</td><t",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "17cb347a673a4caa",
        "value": 0.092,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>52.6%</td><td>142.2%</td><td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.9%</td><td>11.1%</td><td>15.3%</td></tr><tr><td>EPS</td><td>(54)</td><td>27</td><td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "523b44e45ede6add",
        "value": 0.18899999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>142.2%</td><td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.9%</td><td>11.1%</td><td>15.3%</td></tr><tr><td>EPS</td><td>(54)</td><td>27</td><td>41</td><td>99",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "5f1dfc7bbdd44d0a",
        "value": 0.111,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-46.2%</td></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.9%</td><td>11.1%</td><td>15.3%</td></tr><tr><td>EPS</td><td>(54)</td><td>27</td><td>41</td><td>99</td><td>49</t",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "d2f7df1f18b3f138",
        "value": 0.153,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Margin %</td><td>-16.8%</td><td>6.3%</td><td>9.2%</td><td>18.9%</td><td>11.1%</td><td>15.3%</td></tr><tr><td>EPS</td><td>(54)</td><td>27</td><td>41</td><td>99</td><td>49</td><td>67</td><",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "e66e4803d093b06b",
        "value": 0.526,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>27</td><td>41</td><td>99</td><td>49</td><td>67</td></tr><tr><td>YoY%</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-51.1%</td><td>37.3%</td></tr></table> Source: Company info., Jefferies",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "2140af5356bf23f1",
        "value": 1.422,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "41</td><td>99</td><td>49</td><td>67</td></tr><tr><td>YoY%</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-51.1%</td><td>37.3%</td></tr></table> Source: Company info., Jefferies Exhibit 23-Nx",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "fd0262f7706fe305",
        "value": -0.511,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>49</td><td>67</td></tr><tr><td>YoY%</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-51.1%</td><td>37.3%</td></tr></table> Source: Company info., Jefferies Exhibit 23-Nxera BS (mn) <ta",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "dbb0258fbe3b7680",
        "value": 0.373,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>67</td></tr><tr><td>YoY%</td><td>-</td><td>-</td><td>52.6%</td><td>142.2%</td><td>-51.1%</td><td>37.3%</td></tr></table> Source: Company info., Jefferies Exhibit 23-Nxera BS (mn) <table><tr><td></t",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "0b40fdcb49a6d82b",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "e51db71d19e21ea1",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not ",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "7249af3d0b741f53",
        "value": 912.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": "style such as growth or value. ## Other Companies Mentioned in This Report Nxera Pharma (4565 JP: ¥912, BUY) ![Figure 16-0](images/16_0.jpg) Notes: Each box in the Rating and Price Target History char",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "2a397b5d8e6f478a",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "60d3415a17828996",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "94b020b585cbca3c",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "f9264ecdc1f11fef",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157<",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "6c2e0fd70b0cff62",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "fba4190f46babf33",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td>",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "7dca884cbf042a3e",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "d1192144ec692dd6",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "6e7a16cecc78eec6",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 17
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 15,
      "tables_count": 0,
      "numerical_data_count": 171,
      "passages_count": 154,
      "entities_count": 20
    }
  }
}